Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders

Journal of Proteomics

Volumn 73, Issue 11, 2010, Pages 2230-2238

  Zabel, Claus ^a   Nguyen, Huu Phuc ^b   Hin, Sascha C ^a   Hartl, Daniela ^a   Mao, Lei ^a   Klose, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Aging; Alzheimer; Huntington; Neurodegeneration; Parkinson; Proteasome

Indexed keywords

AMYLOID BETA PROTEIN; PROTEASOME; PROTEOME; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; DISEASE COURSE; HUNTINGTON CHOREA; MASS SPECTROMETRY; MITOCHONDRION; NERVE DEGENERATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; RISK FACTOR; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGING; ANIMALS; NEURODEGENERATIVE DISEASES; OXIDATIVE PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOMICS; RISK FACTORS;

EID: 77957220637     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.08.008     Document Type: Review

References (84)

1. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368(9533):387-403.
2. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363(9423):1783-1793.
3. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88(9):1337-1342.
4. HCRG A. Novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72(6):971-983.
5. Hartl D., Rohe M., Mao L., Staufenbiel M., Zabel C., Klose J. Impairment of adolescent hippocampal plasticity in a mouse model for Alzheimer's disease precedes disease phenotype. PLoS ONE 2008, 3(7):e2759.
6. Zabel C., Mao L., Woodman B., Rohe M., Wacker M.A., Klare Y., Koppelstatter A., Nebrich G., Klein O., Grams S., Strand A., Luthi-Carter R., Hartl D., Klose J., Bates G.P. A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. Mol Cell Proteomics 2009, 8(4):720-734.
7. Diedrich M., Mao L., Bernreuther C., Zabel C., Nebrich G., Kleene R., Klose J. Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice. Proteomics 2008, 8(6):1266-1275.
8. Zabel C., Chamrad D.C., Priller J., Woodman B., Meyer H.E., Bates G.P., Klose J. Alterations in the mouse and human proteome caused by Huntington's disease. Mol Cell Proteomics 2002, 1(5):366-375.
9. Zabel C., Sagi D., Kaindl A.M., Steireif N., Klare Y., Mao L., Peters H., Wacker M.A., Kleene R., Klose J. Comparative proteomics in neurodegenerative and non-neurodegenerative diseases suggest nodal point proteins in regulatory networking. J Proteome Res 2006, 5(8):1948-1958.
10. Mao L., Zabel C., Wacker M.A., Nebrich G., Sagi D., Schrade P., Bachmann S., Kowald A., Klose J. Estimation of the mtDNA mutation rate in aging mice by proteome analysis and mathematical modeling. Exp Gerontol 2006, 41(1):11-24.
11. Hartl D., Irmler M., Romer I., Mader M.T., Mao L., Zabel C., de Angelis M.H., Beckers J., Klose J. Transcriptome and proteome analysis of early embryonic mouse brain development. Proteomics 2008, 8(6):1257-1265.
12. Zabel C., Andreew A., Mao L., Hartl D. Protein expression overlap: more important than which proteins change in expression?. Expert Rev Proteomics 2008, 5(2):187-205.
13. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63(3):287-303.
14. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., Chen F., Shibata N., Lunetta K.L., Pardossi-Piquard R., Bohm C., Wakutani Y., Cupples L.A., Cuenco K.T., Green R.C., Pinessi L., Rainero I., Sorbi S., Bruni A., Duara R., Friedland R.P., Inzelberg R., Hampe W., Bujo H., Song Y.Q., Andersen O.M., Willnow T.E., Graff-Radford N., Petersen R.C., Dickson D., Der S.D., Fraser P.E., Schmitt-Ulms G., Younkin S., Mayeux R., Farrer L.A., St.George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007, 39(2):168-177.
15. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997, 94(24):13287-13292.
16. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006, 7(9):940-946.
17. Morrissette D.A., Parachikova A., Green K.N., LaFerla F.M. Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem 2009, 284(10):6033-6037.
18. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81(2):741-766.
19. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009, 110(4):1129-1134.
20. Walsh D.M., Selkoe D.J. A beta oligomers-a decade of discovery. J Neurochem 2007, 101(5):1172-1184.
21. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39(6):889-909.
22. da Conceicao F.S., Ngo-Abdalla S., Houzel J.C., Rehen S.K. Murine model for Parkinson's disease: from 6-OH dopamine lesion to behavioral test. J Vis Exp 2010, (35).
23. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219(4587):979-980.
24. Heikkila R.E., Sonsalla P.K. The use of the MPTP-treated mouse as an animal model of parkinsonism. Can J Neurol Sci 1987, 14(3 Suppl):436-440.
25. Ogawa N., Mizukawa K., Hirose Y., Kajita S., Ohara S., Watanabe Y. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur Neurol 1987, 26(Suppl 1):16-23.
26. Shimohama S., Sawada H., Kitamura Y., Taniguchi T. Disease model: Parkinson's disease. Trends Mol Med 2003, 9(8):360-365.
27. Fujita M., Sekigawa A., Sekiyama K., Sugama S., Hashimoto M. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?. J Neurol 2009, 256(Suppl 3):286-292.
28. Maguire-Zeiss K.A., Federoff H.J. Convergent pathobiologic model of Parkinson's disease. Ann NY Acad Sci 2003, 991:152-166.
29. Lu X.H. BAC to degeneration bacterial artificial chromosome (BAC)-mediated transgenesis for modeling basal ganglia neurodegenerative disorders. Int Rev Neurobiol 2009, 89:37-56.
30. Sowell R.A., Owen J.B., Butterfield D.A. Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res Rev 2009, 8(1):1-17.
31. Periquet M., Corti O., Jacquier S., Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J Neurochem 2005, 95(5):1259-1276.
32. Gautier C.A., Kitada T., Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 2008, 105(32):11364-11369.
33. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004, 279(18):18614-18622.
34. Ekstrand M.I., Galter D. The MitoPark Mouse-an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat Disord 2009, 15(Suppl 3):S185-S188.
35. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87(3):493-506.
36. Hickey M.A., Gallant K., Gross G.G., Levine M.S., Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 2005, 20(1):1-11.
37. Hockly E., Woodman B., Mahal A., Lewis C.M., Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull 2003, 61(5):469-479.
38. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90(3):537-548.
39. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003, 12(13):1555-1567.
40. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 2008, 28(24):6182-6195.
41. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 2001, 10(2):137-144.
42. Menalled L.B., Sison J.D., Wu Y., Olivieri M., Li X.J., Li H., Zeitlin S., Chesselet M.F. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci 2002, 22(18):8266-8276.
43. Wheeler V.C., Gutekunst C.A., Vrbanac V., Lebel L.A., Schilling G., Hersch S., Friedlander R.M., Gusella J.F., Vonsattel J.P., Borchelt D.R., MacDonald M.E. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 2002, 11(6):633-640.
44. Harman D. The aging process. Proc Natl Acad Sci USA 1981, 78(11):7124-7128.
45. Quarrie J.K., Riabowol K.T. Murine models of life span extension. Sci Aging Knowledge Environ 2004, (31). re5.
46. Parrella, E.; Longo, V. D., Insulin/IGF-I and related signaling pathways regulate aging in nondividing cells: from yeast to the mammalian brain. ScientificWorldJournal 10, 161-77.
47. Piper M.D., Selman C., McElwee J.J., Partridge L. Separating cause from effect: how does insulin/IGF signalling control lifespan in worms, flies and mice?. J Intern Med 2008, 263(2):179-191.
48. Landis G.N., Tower J. Superoxide dismutase evolution and life span regulation. Mech Ageing Dev 2005, 126(3):365-379.
49. Jackson M.J. Skeletal muscle aging: role of reactive oxygen species. Crit Care Med 2009, 37(10 Suppl):S368-S371.
50. Shimizu T., Shirasawa T. Anti-aging research using Mn-SOD conditional knockout mice. Yakugaku Zasshi 2010, 130(1):19-24.
51. Ceballos-Picot I., Nicole A., Clement M., Bourre J.M., Sinet P.M. Age-related changes in antioxidant enzymes and lipid peroxidation in brains of control and transgenic mice overexpressing copper-zinc superoxide dismutase. Mutat Res 1992, 275(3-6):281-293.
52. Perez V.I., Van Remmen H., Bokov A., Epstein C.J., Vijg J., Richardson A. The overexpression of major antioxidant enzymes does not extend the lifespan of mice. Aging Cell 2009, 8(1):73-75.
53. Schriner S.E., Linford N.J., Martin G.M., Treuting P., Ogburn C.E., Emond M., Coskun P.E., Ladiges W., Wolf N., Van Remmen H., Wallace D.C., Rabinovitch P.S. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 2005, 308(5730):1909-1911.
54. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N Engl J Med 2010, 362(4):329-344.
55. Whitworth A.J., Pallanck L.J. The PINK1/Parkin pathway: a mitochondrial quality control system?. J Bioenerg Biomembr 2009, 41(6):499-503.
56. Sack G.H. Mitochondrial matters in Huntington disease. J Bioenerg Biomembr 2010, 42:189-191.
57. Mao L., Roemer I., Nebrich G., Klein O., Koppelstaetter A., Hin S., Hartl D., Zabel C. Aging in mouse brain is a cell/tissue-level phenomenon exacerbated by functional proteasome loss. J Proteome Res 2010, 9(7):3551-3560.
58. Yang S., Liu T., Li S., Zhang X., Ding Q., Que H., Yan X., Wei K., Liu S. Comparative proteomic analysis of brains of naturally aging mice. Neuroscience 2008, 154(3):1107-1120.
59. Schmidt F., Donahoe S., Hagens K., Mattow J., Schaible U.E., Kaufmann S.H., Aebersold R., Jungblut P.R. Complementary analysis of the Mycobacterium tuberculosis proteome by two-dimensional electrophoresis and isotope-coded affinity tag technology. Mol Cell Proteomics 2004, 3(1):24-42.
60. Zabel C., Klose J. High-resolution large-gel 2DE. Methods Mol Biol 2009, 519:311-338.
61. Zabel C., Klose J. Protein extraction for 2DE. Methods Mol Biol 2009, 519:171-196.
62. Klose J., Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 1995, 16(6):1034-1059.
63. Berth M., Moser F.M., Kolbe M., Bernhardt J. The state of the art in the analysis of two-dimensional gel electrophoresis images. Appl Microbiol Biotechnol 2007, 76(6):1223-1243.
64. Bennett E.J., Shaler T.A., Woodman B., Ryu K.Y., Zaitseva T.S., Becker C.H., Bates G.P., Schulman H., Kopito R.R. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448(7154):704-708.
65. Ragland M., Hutter C., Zabetian C., Edwards K. Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis. Am J Epidemiol 2009, 170(11):1344-1357.
66. Pankratz N.D., Wojcieszek J., Foroud T. Parkinson Disease Overview 1993.
67. Voges D., Zwickl P., Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999, 68:1015-1068.
68. Yorimitsu T., Klionsky D.J. Autophagy: molecular machinery for self-eating. Cell Death Differ 2005, 12(Suppl 2):1542-1552.
69. Kowald A., Kirkwood T.B. Explaining fruit fly longevity. Science 1993, 260(5114):1664-1665. author reply 1665-6.
70. Kowald A., Kirkwood T.B. Accuracy of tRNA charging and codon: anticodon recognition; relative importance for cellular stability. J Theor Biol 1993, 160(4):493-508.
71. Bonifacino J.S., Weissman A.M. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu Rev Cell Dev Biol 1998, 14:19-57.
72. Kirkwood T.B., Kowald A. Network theory of aging. Exp Gerontol 1997, 32(4-5):395-399.
73. Calabrese B., Shaked G.M., Tabarean I.V., Braga J., Koo E.H., Halpain S. Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci 2007, 35(2):183-193.
74. Finley D., Bartel B., Varshavsky A. The tails of ubiquitin precursors are ribosomal proteins whose fusion to ubiquitin facilitates ribosome biogenesis. Nature 1989, 338(6214):394-401.
75. Carmichael P.L., Hipkiss A.R. Age-related changes in proteolysis of aberrant crystallin in bovine lens cell-free preparations. Mech Ageing Dev 1989, 50(1):37-48.
76. Davies J.E., Sarkar S., Rubinsztein D.C. The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. BMC Biochem 2007, 8(Suppl 1):S2.
77. Rogers N., Paine S., Bedford L., Layfield R. Review: the ubiquitin-proteasome system: contributions to cell death or survival in neurodegeneration. Neuropathol Appl Neurobiol 2010, 36(2):113-124.
78. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 2008, 12(2):363-373.
79. Vonsattel J.P., DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998, 57(5):369-384.
80. Schapira A.H. Mitochondrial dysfunction in neurodegenerative disorders. Biochim Biophys Acta 1998, 1366(1-2):225-233.
81. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., Nebes R.D., Saxton J.A., Snitz B.E., Aizenstein H.A., Wolk D.A., Dekosky S.T., Mathis C.A., Klunk W.E. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 2009, 29(47):14770-14778.
82. Mosconi L., Pupi A., De Leon M.J. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann NY Acad Sci 2008, 1147:180-195.
83. Mochel F., Charles P., Seguin F., Barritault J., Coussieu C., Perin L., Le Bouc Y., Gervais C., Carcelain G., Vassault A., Feingold J., Rabier D., Durr A. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2007, 2(7):e647.
84. Tang C.C., Poston K.L., Dhawan V., Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 2010, 30(3):1049-1056.